18th Nov 2019 11:51
(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said testing has demonstrated that its CDX antibody is potentially a life-saving treatment for sufferers of forms of blood cancer.
The biopharmaceuticals firm is developing the treatment alongside an unnamed "global pharmaceutical company", which it refers to as GlobalCo.
Work with the company has entered its second phase, Hemogenyx said.
Hemogenyx added: "Hemogenyx and GlobalCo remain optimistic as to the outcome of these tests based on results to date and look forward to providing further updates as the development work progresses."
Alongside its development work with the undisclosed firm, the company is researching CDX's effectiveness in treating acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndromes.
Testing of humanised mice, rodents carrying human genes, demonstrated that the CDX product candidate could provide "life-saving treatments" against the three blood cancers.
Hemogenyx said: "The use of CDX as a therapy against blood malignancies is beyond what was anticipated when the company listed in 2017. At this time CDX was being developed purely as a conditioning product for bone marrow transplantation."
Elsewhere, Hemogenyx-Cell SPRL, a Belgian subsidiary developing the Hu-PHEC stem cell therapy, has received a funding offer from local authorities.
The firm explained: "The directors are currently reviewing the terms of this offer and the conditions attached."
Shares in the company were 7.7% higher at 2.10 pence each in London on Monday morning.
By Eric Cunha; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
Hemogenyx